SEARCH

SEARCH BY CITATION

References

  • 1
    Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 1987; 262: 1662535.
  • 2
    Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J, Rauvala H. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 1991; 266: 167229.
  • 3
    Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989; 243: 10569.
  • 4
    Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001; 26: 1523.
  • 5
    Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999; 19: 523746.
  • 6
    Calogero S, Grassi F, Aguzzi A et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Gen 1999; 22: 27680.
  • 7
    Rauvala H, Merenmies J, Pihlaskari R, Korkolainen M, Huhtala ML, Panula P. The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol 1988; 107: 2293305.
  • 8
    Parkkinen J, Raulo E, Merenmies J et al. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993; 268: 1972638.
  • 9
    Parkkinen J, Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 1991; 266: 167305.
  • 10
    Melloni E, Sparatore B, Patrone M, Pessino A, Passalacqua M, Pontremoli S. Extracellular release of the ‘differentiation enhancing factor’, a HMG1 protein type, is an early step in murine erythroleukemia cell differentiation. FEBS Lett 1995; 368: 46670.
  • 11
    Sparatore B, Passalacqua M, Patrone M, Melloni E, Pontremoli S. Extracellular high-mobility group 1 protein is essential for murine erythroleukaemia cell differentiation. Biochem J 1996; 320: 2536.
  • 12
    Passalacqua M, Zicca A, Sparatore B, Patrone M, Melloni E, Pontremoli S. Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation. FEBS Lett 1997; 400: 2759.
  • 13
    Passalacqua M, Patrone M, Picotti GB et al. Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation. Neuroscience 1998; 82: 10218.
  • 14
    Nair SM, Zhao Z, Chou DK, Tobet SA, Jungalwala FB. Expression of HNK-1 carbohydrate and its binding protein, SBP-1, in apposing cell surfaces in cerebral cortex and cerebellum. Neuroscience 1998; 85: 75971.
  • 15
    Zhao Z, Chou DK, Nair SM, Tobet S, Jungalwala FB. Expression of sulfoglucuronyl (HNK-1) carbohydrate and its binding protein (SBP-1) in developing rat cerebellum. Brain Res Dev Brain Res 2000; 120: 16580.
  • 16
    Zhao Z, Nair SM, Chou DK, Tobet SA, Jungalwala FB. Expression and role of sulfoglucuronyl (HNK-1) carbohydrate and its binding protein SBP-1 in developing rat cerebral cortex. J Neurosci Res 2000; 62: 186205.
  • 17
    Chou DK, Evans JE, Jungalwala FB. Identity of nuclear high-mobility-group protein, HMG-1, and sulfoglucuronyl carbohydrate-binding protein, SBP-1, in brain. J Neurochem 2001; 77: 12031.
  • 18
    Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 2000; 113: 61120.
  • 19
    Kuniyasu H, Oue N, Wakikawa A et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 16370.
  • 20
    Kawahara N, Tanaka T, Yokomizo A et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996; 56: 53303.
  • 21
    Xiang YY, Wang DY, Tanaka M et al. Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa. Int J Cancer 1997; 74: 16.
  • 22
    Taguchi A, Blood DC, Del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 35460.
  • 23
    Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001; 48: 15778.
  • 24
    Melloni E, Sparatore B, Patrone M, Pessino A, Passalacqua M, Pontremoli S. Identity in molecular structure between ‘differentiation enhancing factor’ of murine erythroleukemia cells and the 30 kD heparin-binding protein of developing rat brain. Biochem Biophys Res Commun 1995; 210: 829.
  • 25
    Sparatore B, Melloni E, Patrone M, Passalacqua M, Pontremoli S. A 6 kDa protein homologous to the N-terminus of the HMG1 protein promoting stimulation of murine erythroleukemia cell differentiation. FEBS Lett 1996; 386: 958.
  • 26
    Sparatore B, Patrone M, Passalacqua M et al. Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation. Biochem J 2001; 357: 56974.
  • 27
    Huttunen HJ, Kuja-Panula J, Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002; 277: 3863546.
  • 28
    Zhai RG, Vardinon-Friedman H, Cases-Langhoff C et al. Assembling the presynaptic active zone: a characterization of an active one precursor vesicle. Neuron 2001; 29: 13143.
  • 29
    Daston MM, Ratner N. Expression of P30, a protein with adhesive properties, in Schwann cells and neurons of the developing and regenerating peripheral nerve. J Cell Biol 1991; 112: 122939.
  • 30
    Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 24851.
  • 31
    Ombrellino M, Wang H, Ajemian MS et al. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet 1999; 354: 14467.
  • 32
    Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 29504.
  • 33
    Kokkola R, Sundberg E, Ulfgren AK et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002; 46: 2598603.
  • 34
    Ulloa L, Batliwalla FM, Andersson U, Gregersen PK, Tracey KJ. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 2003; 48: 87681.
  • 35
    Taniguchi N, Kawahara K, Yone K et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48: 97181.
  • 36
    Pullerits R, Jonsson IM, Verdrengh M et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum 2003; 48: 1693700.
  • 37
    Wang H, Vishnubhakat JM, Bloom O et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126: 38992.
  • 38
    Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res 1993; 21: 342736.
  • 39
    Weir HM, Kraulis PJ, Hill CS, Raine AR, Laue ED, Thomas JO. Structure of the HMG box motif in the B-domain of HMG1. EMBO J 1993; 12: 13119.
  • 40
    Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989; 9: 2132.
  • 41
    Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002; 62: 480511.
  • 42
    Aizawa S, Nishino H, Saito K, Kimura K, Shirakawa H, Yoshida M. Stimulation of transcription in cultured cells by high mobility group protein 1: essential role of the acidic carboxyl-terminal region. Biochemistry 1994; 33: 146905.
  • 43
    Banerjee S, Kundu TK. The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription. Nucleic Acids Res 2003; 31: 323647.
  • 44
    Kallijarvi J, Haltia M, Baumann MH. Amphoterin includes a sequence motif which is homologous to the Alzheimer's beta-amyloid peptide (Abeta), forms amyloid fibrils in vitro, and binds avidly to Abeta. Biochemistry 2001; 40: 100327.
  • 45
    Takata K, Kitamura Y, Kakimura J et al. Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem Biophys Res Commun 2003; 301: 699703.
  • 46
    Li J, Kokkola R, Tabibzadeh S et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 2003; 9: 3745.
  • 47
    Ferrari S, Ronfani L, Calogero S, Bianchi ME. The mouse gene coding for high mobility group 1 protein (HMG1). J Biol Chem 1994; 269: 288038.
  • 48
    Gariboldi M, De Gregorio L, Ferrari S et al. Mapping of the Hmg1 gene and of seven related sequences in the mouse. Mamm Genome 1995; 6: 5815.
  • 49
    Bentley DR, Deloukas P, Dunham A et al. The physical maps for sequencing human chromosomes 1, 6, 9, 10, 13, 20 and X. Nature 2001; 409: 9423.
  • 50
    Blake JA, Richardson JE, Bult CJ, Kadin JA, Eppig JT. The Mouse Genome Database (MGD): the model organism database for the laboratory mouse. Nucleic Acids Res 2002; 30: 1135.
  • 51
    Lum HK, Lee KL. The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron. Biochim Biophys Acta 2001; 1520: 7984.
  • 52
    Guazzi S, Strangio A, Franzi AT, Bianchi ME. HMGB1, an architectural chromatin protein and extracellular signalling factor, has a spatially and temporally restricted expression pattern in mouse brain. Gene Expr Patterns 2003; 3: 2933.
  • 53
    Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 2575261.
  • 54
    Milev P, Chiba A, Haring M et al. High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. J Biol Chem 1998; 273: 69987005.
  • 55
    Daston MM, Ratner N. Amphoterin (P30, HMG-1) and RIP are early markers of oligodendrocytes in the developing rat spinal cord. J Neurocytol 1994; 23: 32332.
  • 56
    Kinoshita M, Hatada S, Asashima M, Noda M. HMG-X, a Xenopus gene encoding an HMG1 homolog, is abundantly expressed in the developing nervous system. FEBS Lett 1994; 352: 1916.
  • 57
    Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000; 84: 108794.
  • 58
    Andersson U, Wang H, Palmblad K et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 56570.
  • 59
    Flohr AM, Rogalla P, Meiboom M et al. Variation of HMGB1 expression in breast cancer. Anticancer Res 2001; 21: 38815.
  • 60
    Brezniceanu ML, Volp K, Bosser S et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. Faseb J 2003; 17: 12957.
  • 61
    Choi YR, Kim H, Kang HJ et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 2003; 63: 218893.
  • 62
    Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003; 10: 4458.
  • 63
    Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 29918.
  • 64
    Bustin M, Neihart NK. Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells. Cell 1979; 16: 1819.
  • 65
    Punnonen EL, Fages C, Wartiovaara J, Rauvala H. Ultrastructural localization of beta-actin and amphoterin mRNA in cultured cells: application of tyramide signal amplification and comparison of detection methods. J Histochem Cytochem 1999; 47: 99112.
  • 66
    Rendon-Mitchell B, Ochani M, Li J et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003; 170: 38907.
  • 67
    Gardella S, Andrei C, Ferrera D et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 9951001.
  • 68
    Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 1915.
  • 69
    Bovolenta P, Fernaud-Espinosa I. Nervous system proteoglycans as modulators of neurite outgrowth. Prog Neurobiol 2000; 61: 11332.
  • 70
    Rauvala H, Peng HB. HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Prog Neurobiol 1997; 52: 12744.
  • 71
    Salmivirta M, Rauvala H, Elenius K, Jalkanen M. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp Cell Res 1992; 200: 44451.
  • 72
    Woods A, Couchman JR. Syndecans: synergistic activators of cell adhesion. Trends Cell Biol 1998; 8: 18992.
  • 73
    Rapraeger AC. Syndecan-regulated receptor signaling. J Cell Biol 2000; 149: 9958.
  • 74
    Jungalwala FB. Expression and biological functions of sulfoglucuronyl glycolipids (SGGLs) in the nervous system – a review. Neurochem Res 1994; 19: 94557.
  • 75
    Mohan PS, Laitinen J, Merenmies J, Rauvala H, Jungalwala FB. Sulfoglycolipids bind to adhesive protein amphoterin (P30) in the nervous system. Biochem Biophys Res Commun 1992; 182: 68996.
  • 76
    Nair SM, Jungalwala FB. Characterization of a sulfoglucuronyl carbohydrate binding protein in the developing nervous system. J Neurochem 1997; 68: 128697.
  • 77
    Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 1498797.
  • 78
    Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99111.
  • 79
    Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 149985004.
  • 80
    Rauvala H, Huttunen HJ, Fages C et al. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 2000; 19: 37787.
  • 81
    Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 94955.
  • 82
    Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000; 11: 36875.
  • 83
    Kislinger T, Fu C, Huber B et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 317409.
  • 84
    Stern D, Yan SD, Schmidt AM, Lamster I. Ligand binding site of RAGE and uses thereof. US Patent Office, Patent application 1997; no. 948131.
  • 85
    Yan SD, Chen X, Fu J et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 68591.
  • 86
    Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889901.
  • 87
    Jones EY, Harlos K, Bottomley MJ et al. Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 A resolution. Nature 1995; 373: 53944.
  • 88
    Srikrishna G, Huttunen HJ, Johansson L et al. N-glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem 2002; 80: 9981008.
  • 89
    Sugaya K, Fukagawa T, Matsumoto K et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994; 23: 40819.
  • 90
    Vissing H, Aagaard L, Tommerup N, Boel E. Localization of the human gene for advanced glycosylation end product-specific receptor (AGER) to chromosome 6p21.3. Genomics 1994; 24: 6068.
  • 91
    Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 1998; 47: 11557.
  • 92
    Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the rage gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50: 150511.
  • 93
    Kankova K, Marova I, Zahejsky J et al. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 2001; 50: 115260.
  • 94
    Kankova K, Vasku A, Hajek D, Zahejsky J, Vasku V. Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 1999; 22: 1745.
  • 95
    Liu L, Xiang K. RAGE Gly82Ser polymorphism in diabetic microangiopathy. Diabetes Care 1999; 22: 646.
  • 96
    Poirier O, Nicaud V, Vionnet N et al. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001; 50: 12148.
  • 97
    Hofmann MA, Drury S, Hudson BI et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 12335.
  • 98
    Vasku V, Kankova K, Vasku A et al. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch Dermatol Res JID - 8000462 2002; 294: 12730.
  • 99
    Kankova K, Zahejsky J, Marova I et al. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J Diabetes Compl 2001; 15: 18592.
  • 100
    Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498506.
  • 101
    Li JF, Qu XQ, Schmidt AM. Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem 1998; 273: 308708.
  • 102
    Brett J, Schmidt AM, Yan SD et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699712.
  • 103
    Ritthaler U, Deng Y, Zhang Y et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995; 146: 68894.
  • 104
    Miyata T, Hori O, Zhang J et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996; 98: 108894.
  • 105
    Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 988997.
  • 106
    Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 1991924.
  • 107
    Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096105.
  • 108
    Barbas JA, Chaix JC, Steinmetz M, Goridis C. Differential splicing and alternative polyadenylation generates distinct NCAM transcripts and proteins in the mouse. EMBO J 1988; 7: 62532.
  • 109
    Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7: 7117.
  • 110
    Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003; 550: 10713.
  • 111
    Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 178104.
  • 112
    Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol 2002; 3: 3040.
  • 113
    Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001; 11: 4717.
  • 114
    Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001; 114: 271322.
  • 115
    Dickson BJ. Rho GTPases in growth cone guidance. Curr Opin Neurobiol 2001; 11: 10310.
  • 116
    Schmidt AM, Hasu M, Popov D et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994; 91: 880711.
  • 117
    Goova MT, Li J, Kislinger T et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 51325.
  • 118
    Yan SD, Zhu H, Zhu A et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6: 64351.
  • 119
    Yan SD, Zhu H, Fu J et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer's disease. Proc Natl Acad Sci USA 1997; 94: 5296301.
  • 120
    Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 185363.
  • 121
    Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999; 39: 67101.
  • 122
    Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395403.
  • 123
    Bierhaus A, Illmer T, Kasper M et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 226271.
  • 124
    Ichikawa K, Yoshinari M, Iwase M et al. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis 1998; 136: 2817.
  • 125
    Murphy M, Dutton R, Koblar S, Cheema S, Bartlett P. Cytokines which signal through the LIF receptor and their actions in the nervous system. Prog Neurobiol 1997; 52: 35578.
  • 126
    Kuja-Panula J, Kiiltomaki M, Yamashiro T, Rouhiainen A, Rauvala H. AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats. J Cell Biol 2003; 160: 96373.
  • 127
    Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 1999; 68: 82161.
  • 128
    Denk A, Wirth T, Baumann B. NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev 2000; 11: 30320.
  • 129
    Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 63768.
  • 130
    Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999; 1450: 191231.
  • 131
    Novitskaya V, Grigorian M, Kriajevska M et al. Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons. J Biol Chem 2000; 275: 4127886.
  • 132
    Winningham-Major F, Staecker JL, Barger, SW, Coats S, Van Eldik LJ. Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J Cell Biol 1989; 109: 306371.
  • 133
    Van Eldik LJ, Christie-Pope B, Bolin LM, Shooter EM, Whetsell WO Jr. Neurotrophic activity of S-100 beta in cultures of dorsal root ganglia from embryonic chick and fetal rat. Brain Res 1991; 542: 2805.
  • 134
    Bhattacharyya A, Oppenheim RW, Prevette D, Moore BW, Brackenbury R, Ratner N. S100 is present in developing chicken neurons and Schwann cells and promotes motor neuron survival in vivo. J Neurobiol 1992; 23: 45166.
  • 135
    Haglid KG, Yang Q, Hamberger A, Bergman S, Widerberg A, Danielsen N. S-100beta stimulates neurite outgrowth in the rat sciatic nerve grafted with acellular muscle transplants. Brain Res 1997; 753: 196201.
  • 136
    Iwasaki Y, Shiojima T, Kinoshita M. S100 beta prevents the death of motor neurons in newborn rats after sciatic nerve section. J Neurol Sci 1997; 151: 712.
  • 137
    Mariggio MA, Fulle S, Calissano P, Nicoletti I, Fano G. The brain protein S-100ab induces apoptosis in PC12 cells. Neuroscience 1994; 60: 2935.
  • 138
    Hu J, Ferreira A, Van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem 1997; 69: 2294301.
  • 139
    Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21: 90510.
  • 140
    Mikkelsen SE, Novitskaya V, Kriajevska M et al. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. J Neurochem 2001; 79: 76776.
  • 141
    Moroz OV, Antson AA, Dodson GG et al. Crystallization and preliminary X-ray diffraction analysis of human calcium-binding protein S100A12. Acta Crystallogr Biol Crystallogr 2000; 56: 18991.
  • 142
    Drohat AC, Baldisseri DM, Rustandi RR, Weber DJ. Solution structure of calcium-bound rat S100B(betabeta) as determined by nuclear magnetic resonance spectroscopy. Biochemistry 1998; 37: 272940.
  • 143
    Degryse B, Bonaldi T, Scaffidi P et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197206.
  • 144
    Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 91: 215568.
  • 145
    McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000; 6: 14956.
  • 146
    Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 3008.